Latest Conference Coverage

Yogesh Shah, MD, MPH, FAAFP, discusses how earlier identification of Alzheimer pathology with P-tau217 could change the patient journey, from treatment opportunities to long-term planning and dementia risk reduction.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

In this episode, Dr. Yogesh Shah, MD, explores the practical implications of P-tau217 noninferiority and why broader access to blood-based testing could transform Alzheimer's diagnosis.

Dr. Yogesh Shah, MD, reviews the evidence supporting P-tau217 as a reliable rule-in biomarker for Alzheimer's pathology and discusses how clinicians can incorporate blood-based testing into patient evaluation.

As research expands beyond amyloid and tau, experts discuss how novel biomarkers could identify multiple coexisting neurodegenerative pathologies and pave the way for more personalized treatment approaches based on each patient’s unique disease profile. [WATCH TIME: 9 Minutes]

John Corboy, MD, professor of neurology at the University of Colorado, discussed recent findings focused on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis.

As research moves toward treating Alzheimer disease before symptoms emerge, experts highlight the potential of plasma biomarkers to identify at-risk individuals, guide clinical trial enrollment, and create a window for intervention before irreversible neuronal damage occurs. [WATCH TIME: 6 Mintes]

Actress Jamie Lynn Sigler discussed how patient education, treatment adherence, and self-advocacy have shaped her approach to living with multiple sclerosis at the 2026 CMSC Annual Meeting.

Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

The Trojanowski Professor for Neurodegenerative Disease Research at the University of Pennsylvania, discusses how postmortem and longitudinal imaging findings provide new insights into the potential downstream effects of amyloid clearance on tau pathology and neurodegeneration in Alzheimer disease. [WATCH TIME: 3 Mintutes]

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

At CMSC 2026, the assistant professor of neurology at NYU Grossman School of Medicine talked about how optical coherence tomography contributes to the updated 2024 McDonald criteria for multiple sclerosis. [WATCH TIME: 4 minutes]

The professor of neurosciences and head of neuropsychology at Fleni Institute in Buenos Aires, Argentina, discussed findings from the LatAm-FINGERS study that suggest structured, multidomain lifestyle interventions may offer meaningful cognitive benefits among older adults in Latin America. [WATCH TIME: 3 minutes]

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Yogesh Shah, MD, explains the biological basis of P-tau217 and why blood-based biomarker testing is emerging as a practical, highly accurate tool for identifying Alzheimer's pathology.

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

At AAIC 2026, the head of sciences at the Alzheimer Center Amsterdam, discusses the growing role of biomarkers in understanding the biological complexity of Alzheimer disease and advancing more personalized approaches to diagnosis and treatment. [WATCH TIME: 3 minutes]

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, recaps his PNS 2026 presentation on current and emerging biomarkers in peripheral nerve disease, from neurofilament light chain to muscle MRI and microRNA.

At SLEEP 2026, the head of orexin franchise development and neuroscience programs at Takeda discussed new phase 3 data for oveporexton in patients with narcolepsy type 1. [WATCH TIME: 5 minutes]

At SLEEP 2026, the research intern at Beth Israel Deaconess Medical Center described the development of an electronic health record–based machine learning model for obstructive sleep apnea screening. [WATCH TIME: 3 minutes]

Understanding how amyloid pathology develops years before symptoms emerge is essential to appreciating the growing role of blood-based biomarkers in earlier Alzheimer disease detection.

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

At SLEEP 2026, the sleep medicine specialist at University of Arizona discussed the new American Academy of Sleep Medicine guideline on the use of combination therapy in adults with chronic insomnia. [WATCH TIME: 5 minutes]